文献速递免疫规划传染病防控与疫情报告

2025-26季美国流感疫苗中期效果估计

Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2026-03-12

基于美国三个呼吸道病毒疫苗效果网络,采用检测阴性病例对照设计,评估2025-26流感季流感疫苗效果。儿童青少年中对门诊就诊VE为38%-41%,对住院VE为41%;成人中对门诊就诊VE为22%-34%,对住院VE为30%。尽管本季中期VE低于近期流感季,接种流感疫苗仍提供保护,CDC建议继续接种。

要点

  • 儿童青少年流感疫苗对门诊就诊VE为38%-41%,对住院VE为41%。
  • 成人流感疫苗对门诊就诊VE为22%-34%,对住院VE为30%。
  • 本季中期VE低于近期流感季,但接种仍提供保护,CDC建议接种。

核心结论

  • 2025-26流感季中期疫苗效果低于近期流感季,但流感疫苗接种仍提供针对流感及其相关住院的保护。

研究设计与样本

  • 采用检测阴性病例对照设计,基于美国三个呼吸道病毒疫苗效果网络,纳入2025-26流感季急性呼吸道疾病相关门诊就诊和住院患者。

主要发现

  • 儿童青少年(<18岁)对流感门诊就诊VE为38%-41%,对流感相关住院VE为41%。
  • 成人(≥18岁)对流感门诊就诊VE为22%-34%,对流感相关住院VE为30%。
  • 儿童青少年对甲型流感VE在不同场景为37%(门诊就诊)至42%(住院);成人对甲型流感VE为30%(住院)至34%(门诊就诊)。
  • 儿童青少年对甲型H3N2相关门诊就诊VE为35%,对甲型H3N2相关住院VE为38%。
  • 儿童青少年对乙型流感门诊就诊VE为45%-71%,成人为63%;其他估计无统计学显著性或无法报告。

关键数值与推荐

  • 美国建议所有≥6个月人群每年接种流感疫苗,包括2025-26流感季。
  • CDC建议接种流感疫苗,美国流感疫苗仍对≥6个月人群可用。

临床怎么用

  • 临床应继续按照CDC建议为≥6个月人群接种流感疫苗,尤其关注儿童青少年和成人等高危人群。
  • 尽管本季中期VE较低,接种疫苗仍可降低流感门诊就诊和住院风险。

局限性

  • 其他疫苗效果估计无统计学显著性或不报告,部分亚组结果受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the United States, annual influenza vaccination has been recommended for all persons aged ≥6 months, including during the 2025-26 season. Interim influenza vaccine effectiveness (VE) estimates were calculated for patients with acute respiratory illness-associated outpatient visits and hospitalizations from three U.S. respiratory virus VE networks during the 2025-26 influenza season, using a test-negative case-control design. Among children and adolescents aged <18 years, VE was 38%-41% against influenza outpatient visits and 41% against influenza-associated hospitalization. Among adults aged ≥18 years, VE was 22%-34% against influenza outpatient visits and 30% against influenza-associated hospitalization. Among children and adolescents, VE against influenza A ranged from 37% (against outpatient visits) to 42% (against hospitalization) across settings; among adults, VE against influenza A ranged from 30% (against hospitalization) to 34% (against outpatient visits) across settings. Among children and adolescents, VE against influenza A(H3N2)-associated outpatient visits was 35% and against influenza A(H3N2)-associated hospitalization was 38%. VE against influenza B outpatient visits ranged from 45%-71% among children and adolescents and was 63% among adults. Other estimates of VE were not statistically significant or were not reportable. Although interim influenza VE is lower during the 2025-26 influenza season than it was during recent influenza seasons, these findings demonstrate that influenza vaccination still provides protection against influenza. CDC recommends influenza vaccination; U.S. influenza vaccines remain available for persons aged ≥6 months.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Maloney P, Reeves EL, Wielgosz K, et al. Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026. MMWR Morb Mortal Wkly Rep. 2026. PMID: 41818161. doi:10.15585/mmwr.mm7509a2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。